MUC16 and cervical carcinoma: Recent discoveries have demonstrated significant milestones in management of cervical cancer based on United States of America Food and Drug Administration (USFDA) approved biomarkers such as Squamous Cell Carcinoma Antigen (SCC-Ag) currently implemented to support physicians with rapid screening of women at high risk of cervical neoplasia, and complemented with Cancer Antigen 125 (CA-125), Serum Fragment of Cytokeratins (CYFRA), Soluble CD44 (sCD44), and Carcinoma Embryonic Antigen (CEA) as prognostic markers for pre-treatment prediction and disease monitoring [4].